Mucormycosis is a deadly opportunistic disease caused by a group of fungus named mucormycetes. Fungal spores are normally present in the environment and the immune system of the body prevents them from causing disease in a healthy immunocompetent individual. But when the defense mechanism of the body is compromised such as in the patients of diabetes mellites, neustropenia, organ transplantation recipients, and other immune-compromised states, these fungal spores invade our defense mechanism easily causing a severe systemic infection with approximately 45-80% of case fatality. In the present scenario, during the COVID-19 pandemic, patients are on immunosuppressive drugs, glucocorticoids, thus are at high risk of mucormycosis. Patients with diabetes mellitus are further getting a high chance of infection. Usually, the spores gain entry through our respiratory tract affecting the lungs and paranasal sinuses. Besides, they can also enter through damage into the skin or through the gastrointestinal route. This review article presents the current statistics, the causes of this infection in the human body, and its diagnosis with available recent therapies through recent databases collected from several clinics and agencies. The diagnosis and identification of the infection were made possible through various latest medical techniques such as computed tomography scans, direct microscopic observations, MALDI-TOF mass spectrometry, serology, molecular assay, and histopathology. Mucormycosis is so uncommon, no randomized controlled treatment studies have been conducted. The newer triazoles, posaconazole (POSA) and isavuconazole (ISAV) (the active component of the prodrug isavuconazonium sulfate) may be beneficial in patients who are refractory to or intolerant of Liposomal Amphotericin B. but due to lack of early diagnosis and aggressive surgical debridement or excision, the mortality rate remains high. In the course of COVID-19 treatments, there must be more vigilance and alertness are required from clinicians to evaluate these invasive fungal infections.

Department of Biotechnology Institute of Applied Sciences and Humanities GLA University 281 406 Mathura UP India

See more in PubMed

Aggarwal D, Chander J, Janmeja AK et al (2015) Pulmonary tuberculosis and mucormycosis co-infection in a diabetic patient. Lung India. 32:53–55. 10.4103/0970-2113.148452 PubMed PMC

Alekseyev K, Didenko L, Chaudhry B (2021) Rhinocerebral mucormycosis and COVID-19 pneumonia. J Med Cases 12: 85–89. 10.14740/jmc3637 PubMed PMC

Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006;6:2365–2374. doi: 10.1111/j.1600-6143.2006.01496.x. PubMed DOI

Alvarez E, Sutton DA, Cano J, et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol. 2009;47:1650–1656. doi: 10.1128/JCM.00036-09. PubMed DOI PMC

Ambrosioni J, Bouchuiguir-Wafa K, Garbino J. Emerging invasive zygomycosis in a tertiary care center: Epidemiology and associated risk factors. Int J Infect Dis. 2010;14:e100–e103. doi: 10.1016/j.ijid.2009.11.024. PubMed DOI

Ananda-Rajah MR, Kontoyiannis D. Isavuconazole: a new extended spectrum triazole for invasive mold diseases. Future Microbiol. 2015;10:693–708. doi: 10.2217/fmb.15.34. PubMed DOI

Antony SJ, Parikh MS, Ramirez R, Applebaum B, Friedman G, Do J. Gastrointestinal mucormycosis resulting in a catastrophic outcome in an immunocompetent patient. Infect Dis Rep. 2015;7:60–65. doi: 10.4081/idr.2015.6031. PubMed DOI PMC

Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782–792. doi: 10.1016/S2213-8587(20)30238-2. PubMed DOI PMC

Aras MH, Kara MI, Erkiliç S, Ay S. Mandibular mucormycosis in immunocompromised patients: Report of 2 cases and review of the literature. J Oral Maxillofac Surg. 2012;70:1362–1368. doi: 10.1016/j.joms.2011.05.012. PubMed DOI

Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi. 2020;6:1–17. doi: 10.3390/jof6020091. PubMed DOI PMC

Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect. 2014;20:76–98. doi: 10.1111/1469-0691.12360. PubMed DOI

Artis WM, Patrusky E, Rastinejad F, Duncan RL. Fungistatic mechanism of human transferrin for Rhizopus oryzae and Trichophyton mentagrophytes: Alternative to simple iron deprivation. Infect Immun. 1983;41:1269–1278. doi: 10.1128/iai.41.3.1269-1278.1983. PubMed DOI PMC

Augustine HFM, White C, Bain J. Aggressive combined medical and surgical management of mucormycosis results in disease eradication in 2 pediatric patients. Plast Surg. 2017;25:211–217. doi: 10.1177/2292550317716119. PubMed DOI PMC

Austin CL, Finley PJ, Mikkelson DR, Tibbs B. Mucormycosis: a rare fungal infection in tornado victims. J Burn Care Res. 2014;35:164–171. doi: 10.1097/BCR.0b013e318299d4bb. PubMed DOI

Bagshaw E, Enoch DA, Blackney M, Posthumus J, Kuessner D. Economic impact of treating invasive mold disease with isavuconazole compared with liposomal amphotericin B in the UK. Future Microbiol. 2018;13:1283–1293. doi: 10.2217/fmb-2018-0119. PubMed DOI PMC

Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 — Final Report. N Engl J Med. 2020;383:1813–1826. doi: 10.1056/nejmoa2007764. PubMed DOI PMC

Bernardo RM, Gurung A, Jain D, Malinis MF. Therapeutic challenges of hepatic mucormycosis in hematologic malignancy: a case report and review of the literature. Am J Case Rep. 2016;17:484–489. doi: 10.12659/AJCR.898480. PubMed DOI PMC

Bhaskaran A, Hosseini-Moghaddam SM, Rotstein C, Husain S. Mold infections in lung transplant recipients. Semin Respir Crit Care Med. 2013;34:371–379. doi: 10.1055/s-0033-1348475. PubMed DOI

Bitar D, Lortholary O, Le Strat Y, et al. Population-based analysis of invasive fungal infections, France, 2001–2010. Emerg Infect Dis. 2014;20:1149–1155. doi: 10.3201/eid2007.140087. PubMed DOI PMC

Blauwkamp TA, Thair S, Rosen MJ, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019;4:663–674. doi: 10.1038/s41564-018-0349-6. PubMed DOI

Boelaert JR, De Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection: in vitro and in vivo animal studies. J Clin Invest. 1993;91:1979–1986. doi: 10.1172/JCI116419. PubMed DOI PMC

Bonifaz A, Stchigel AM, Guarro J, et al. Primary cutaneous mucormycosis produced by the new species Apophysomyces mexicanus. J Clin Microbiol. 2014;52:4428–4431. doi: 10.1128/JCM.02138-14. PubMed DOI PMC

Candoni A, Aversa F, Busca A, et al (2015) Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data. J Chemother 27:1–12. 10.1179/1973947814Y.0000000224 PubMed

Cao Y, Wang L, Ma P, Fan W, Gu B, Ju S. Accuracy of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of mycobacteria: a systematic review and meta-analysis. Sci Rep. 2018;8:1–9. doi: 10.1038/s41598-018-22642-w. PubMed DOI PMC

Chakrabarti A, Chatterjee SS, Das A, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad Med J. 2009;85:573–581. doi: 10.1136/pgmj.2008.076463. PubMed DOI

Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335–342. doi: 10.1080/13693780500464930. PubMed DOI

Chakrabarti A, Kaur H, Savio J, et al. Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study) J Crit Care. 2019;51:64–70. doi: 10.1016/j.jcrc.2019.02.005. PubMed DOI

Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother. 2008;52:722–724. doi: 10.1128/AAC.01136-07. PubMed DOI PMC

Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41:60–66. doi: 10.1086/430710. PubMed DOI

Chennamchetty VK, Adimulapu S, Kola BP, Rao MR (2021) Post-COVID pulmonary mucormycosis-a case report. IP Indian J Immunol Respir Med 6: 62–66. 10.18231/j.ijirm.2021.014

Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: Role of surgery and of old and new antifungal agents. Curr Opin Infect Dis. 2016;29:340–345. doi: 10.1097/QCO.0000000000000277. PubMed DOI

Chitasombat MN, Niparuck P. Deferiprone as adjunctive treatment for patients with invasive mucormycosis: A retrospective case series. Infect Dis Rep. 2018;10:7765–7770. doi: 10.4081/idr.2018. PubMed DOI PMC

Choo JY, Park CM, Lee HJ, Lee CH, Goo JM, Im JG. Sequential morphological changes in follow-up CT of pulmonary mucormycosis. Diagnostic Interv Radiol. 2014;20:42–46. doi: 10.5152/dir.2013.13183. PubMed DOI PMC

Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Candida Auris Infect Coronavirus Dis. 2020;26:2694–2696. PubMed PMC

Chowdhary A, Tarai B, Singh A, Sharma A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerg Infect Dis. 2020;26:2694–2696. doi: 10.3201/eid2611.203504. PubMed DOI PMC

Chretien ML, Legouge C, Pagès PB, et al. Emergency and elective pulmonary surgical resection in haematological patients with invasive fungal infections: a report of 50 cases in a single centre. Clin Microbiol Infect. 2016;22:782–787. doi: 10.1016/j.cmi.2015.12.029. PubMed DOI

Clark NM, Weigt SS, Fishbein MC, Kubak B, Belperio JA, Lynch JP. Fungal Infections Complicating Lung Transplantation. Semin Respir Crit Care Med. 2018;39:227–254. doi: 10.1055/s-0037-1617443. PubMed DOI

Coffey MJ, Fantone J, Stirling MC, Lynch JP. Pseudoaneurysm of pulmonary artery in mucormycosis. Radiographic characteristics and management. Am Rev Respir Dis. 1992;145:1487–1490. doi: 10.1164/ajrccm/145.6.1487. PubMed DOI

Corzo-León DE, Chora-Hernández LD, Rodríguez-Zulueta AP, Walsh TJ. Diabetes mellitus as the major risk factor for mucormycosis in Mexico: epidemiology, diagnosis, and outcomes of reported cases. Med Mycol. 2018;56:29–43. doi: 10.1093/mmy/myx017. PubMed DOI

Danion F, Aguilar C, Catherinot E, et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med. 2015;36:692–705. doi: 10.1055/s-0035-1562896. PubMed DOI

Davari HR, Malekhossini SA, Salahi H Allah et al (2003) Outcome of mucormycosis in liver transplantation: four cases and a review of literature. Exp Clin Transplant 1:147–152. https://pubmed.ncbi.nlm.nih.gov/15859921/ PubMed

Denis J, Ledoux MP, Nivoix Y, Herbrecht R. Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity. J Mycol Med. 2018;28:8–14. doi: 10.1016/j.mycmed.2018.02.005. PubMed DOI

Devana SK, Gupta VG, Mavuduru RS, et al. Isolated renal mucormycosis in immunocompetent hosts: Clinical spectrum and management approach. Am J Trop Med Hyg. 2019;100:791–797. doi: 10.4269/ajtmh.18-0103. PubMed DOI PMC

DiPippo AJ, Rausch CR, Kontoyiannis DP (2019) Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses 62:81–86. 10.1111/myc.12851 PubMed

Dimaka K, Mallis A, Naxakis SS, et al. Chronic rhinocerebral mucormycosis: a rare case report and review of the literature. Mycoses. 2014;57:699–702. doi: 10.1111/myc.12219. PubMed DOI

Do Monte ES, Dos Santos MEL, Ribeiro IB, et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc. 2020;53:746–749. doi: 10.5946/CE.2020.180. PubMed DOI PMC

Dykhuizen RS, Kerr KN, Soutar RL. Air crescent sign and fatal haemoptysis in pulmonary mucormycosis. Scand J Infect Dis. 1994;26:498–501. doi: 10.3109/00365549409008629. PubMed DOI

Elgarten CW, Levy EM, Mattei P, Fisher BT, Olson TS, Freedman JL. Successful treatment of pulmonary mucormycosis in two pediatric hematopoietic stem cell transplant patients. Pediatr Transplant. 2018;22:1–5. doi: 10.1111/petr.13270. PubMed DOI

Epstein JB, Kupferman SB, Zabner R, et al. Early diagnosis and successful management of oral mucormycosis in a hematopoietic stem cell transplant recipient: case report and literature review. Support Care Cancer. 2016;24:3343–3346. doi: 10.1007/s00520-016-3170-x. PubMed DOI

Frater JL, Hall GS, Procop GW. Histologic features of zygomycosis: Emphasis on perineural invasion and fungal morphology. Arch Pathol Lab Med. 2001;125:375–378. doi: 10.1043/0003-9985(2001)125<0375:HFOZ>2.0.CO;2. PubMed DOI

Furfaro E, Signori A, Di Grazia C, et al. Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother. 2019;74:2341–2346. doi: 10.1093/jac/dkz188. PubMed DOI

Gamarra S, Chaves MS, Cabeza MS, et al. Mucormycosis outbreak due to Rhizopus microsporus after arthroscopic anterior cruciate ligament reconstruction surgery evaluated by RAPD and MALDI-TOF Mass spectrometry. J Mycol Med. 2018;28:617–622. doi: 10.1016/j.mycmed.2018.09.002. PubMed DOI

Garcia-Vidal C, Upton A, Kirby KA, Marr KA. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis. 2008;47:1041–1050. doi: 10.1086/591969. PubMed DOI PMC

Geerlings SE, Hoepelman AIM. Immune dysfunction in patients with diabetes mellitus (DM) FEMS Immunol Med Microbiol. 1999;26:259–265. doi: 10.1016/S0928-8244(99)00142-X. PubMed DOI

Gholinejad-Ghadi N, Shokohi T, Seifi Z, et al. Identification of Mucorales in patients with proven invasive mucormycosis by polymerase chain reaction in tissue samples. Mycoses. 2018;61:909–915. doi: 10.1111/myc.12837. PubMed DOI

Graves B, Morrissey CO, Wei A, et al. Isavuconazole as salvage therapy for mucormycosis. Med Mycol Case Rep. 2016;11:36–39. doi: 10.1016/j.mmcr.2016.03.002. PubMed DOI PMC

Greenberg RN, Mullane K, Van Burik JAH, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50:126–133. doi: 10.1128/AAC.50.1.126-133.2006. PubMed DOI PMC

Grossi P, Farina C, Fiocchi R DGD (2000) Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 70:112–116. https://pubmed.ncbi.nlm.nih.gov/10919584/ PubMed

Guimarães LFA, Halpern M, de Lemos AS, et al. Invasive fungal disease in renal transplant recipients at a Brazilian center: local epidemiology matters. Transplant Proc. 2016;48:2306–2309. doi: 10.1016/j.transproceed.2016.06.019. PubMed DOI

Guinea J, Escribano P, Vena A, et al. Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS ONE. 2017;12:1–10. doi: 10.1371/journal.pone.0179136. PubMed DOI PMC

Haas BM, Clayton JD, Elicker BM, Ordovas KG, Naeger DM. CT-guided percutaneous lung biopsies in patients with suspicion for infection may yield clinically useful information. Am J Roentgenol. 2017;208:459–463. doi: 10.2214/AJR.16.16255. PubMed DOI

Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin Respir Crit Care Med. 2011;32:693–702. doi: 10.18093/0869-0189-2018-28-2-243-247. PubMed DOI

Hammer MM, Madan R, Hatabu H. Pulmonary mucormycosis: radiologic features at presentation and over time. Am J Roentgenol. 2018;210:742–747. doi: 10.2214/AJR.17.18792. PubMed DOI

Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. The Lancet Microbe. 2020;1:e245–e253. doi: 10.1016/S2666-5247(20)30115-4. PubMed DOI PMC

Hanley B, Naresh KN, Roufosse C, Nicholson AG, Weir J, Cooke GS, Thursz M, Manousou P, Corbett R, Goldin R. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1:e245–e253. doi: 10.1016/S2666-5247(20)30115-4. PubMed DOI PMC

Hata DJ, Buckwalter SP, Pritt BS, Roberts GD, Wengenack NL. Real-time PCR method for detection of zygomycetes. J Clin Microbiol. 2008;46:2353–2358. doi: 10.1128/JCM.01552-08. PubMed DOI PMC

Husain S, Silveira FP, Azie N, Franks B, Horn D. Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance® registry analysis. Med Mycol. 2017;55:269–277. doi: 10.1093/mmy/myw086. PubMed DOI

Ibrahim AS, Gebermariam T, Fu Y, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest. 2007;117:2649–2657. doi: 10.1172/JCI32338. PubMed DOI PMC

Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of mucormycosis. Clin Infect Dis. 2012;54:1–7. doi: 10.1093/cid/cir865. PubMed DOI PMC

IDF (2019). IDF Diabetes Atlas. https://diabetesatlas.org/en/resources/. (Accessed 4 Sept 2021)

Ino K, Nakase K, Nakamura A, et al. Management of pulmonary mucormycosis based on a polymerase chain reaction (Pcr) diagnosis in patients with hematologic malignancies: a report of four cases. Intern Med. 2017;56:707–711. doi: 10.2169/internalmedicine.56.7647. PubMed DOI PMC

Jamadar DA, Kazerooni EA, Daly BD, White CS, Gross BH. Pulmonary zygomycosis: Ct appearance. J Comput Assist Tomogr. 1995;19:733–738. doi: 10.1097/00004728-199509000-00008. PubMed DOI

Jenks JD, Salzer HJF, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:1033–1044. doi: 10.2147/DDDT.S145545. PubMed DOI PMC

Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25:26–34. doi: 10.1016/j.cmi.2018.07.011. PubMed DOI

John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi. 2019;7:298–303. doi: 10.3390/jof7040298. PubMed DOI PMC

Jung J, Kim MY, Lee HJ, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect. 2015;21:684.e11. doi: 10.1016/j.cmi.2015.03.019. PubMed DOI

Kasai M, Harrington SM, Francesconi A, et al. Detection of a molecular biomarker for Zygomycetes by quantitative PCR assays of plasma, bronchoalveolar lavage, and lung tissue in a rabbit model of experimental pulmonary zygomycosis. J Clin Microbiol. 2008;46:3690–3702. doi: 10.1128/JCM.00917-08. PubMed DOI PMC

Kennedy K, Daveson K, Slavin M, et al. Mucormycosis in Australia: contemporary epidemiology and outcomes. Clin Microbiol Infect. 2016;22:775–781. doi: 10.1016/j.cmi.2016.01.005. PubMed DOI

Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after coronavirus disease 2019 infection in a heart transplant recipient–case report and review of literature. J Med Mycol. 2021;31:101125–101130. doi: 10.1016/j.mycmed.2021.101125. PubMed DOI PMC

Koehler P, Bassetti M, Chakrabarti A, et al. Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis. 2021;21:e149–e162. doi: 10.1016/S1473-3099(20)30847-1. PubMed DOI PMC

Koffi D, Bonouman IV, Toure AO, et al. Estimates of serious fungal infection burden in Côte d’Ivoire and country health profile. J Med Mycol. 2021;31:101086. doi: 10.1016/j.mycmed.2020.101086. PubMed DOI

Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect Dis Clin North Am. 2006;20:581–607. doi: 10.1016/j.idc.2006.06.003. PubMed DOI

Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis. 2005;191:1350–1360. doi: 10.1086/428780. PubMed DOI

Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016;16:1–7. doi: 10.1186/s12879-016-2023-z. PubMed DOI PMC

Kontoyiennis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: Overview of the transplant- associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50:1091–1100. doi: 10.1086/651263. PubMed DOI

Kumar C, Jain P, Wadhwa N, Diwaker P, Khan NP. Nosocomial jejunal mucormycosis - An unusual cause of perforation peritonitis. Iran J Pathol. 2017;12:295–300. doi: 10.30699/ijp.2017.25840. PubMed DOI PMC

Kumar G, Adams A, Hererra M, et al. Predictors and outcomes of healthcare-associated infections in COVID-19 patients. Int J Infect Dis. 2021;104:287–292. doi: 10.1016/j.ijid.2020.11.135. PubMed DOI PMC

Kursun E, Turunc T, Demiroglu YZ, Alişkan HE, Arslan AH. Evaluation of 28 cases of mucormycosis. Mycoses. 2015;58(2):82–87. doi: 10.1111/myc.12278. PubMed DOI

Kyvernitakis A, Torres HA, Jiang Y et al (2016) Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clin Microbiol Infect 22:811–e1. 10.1016/j.cmi.2016.03.029 PubMed

Lamoth F, Chung SJ, Damonti L, Alexander BD. Changing epidemiology of invasive mold infections in patients receiving azole prophylaxis. Clin Infect Dis. 2017;64:1619–1621. doi: 10.1093/cid/cix130. PubMed DOI

Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France: the RetroZygo study (2005–2007) Clin Infect Dis. 2012;54:35–43. doi: 10.1093/cid/cir880. PubMed DOI

Lanternier F, Sun HY, Ribaud P, Singh N, Kontoyiannis DP, Lortholary O. Mucormycosis in organ and stem cell transplant recipients. Clin Infect Dis. 2012;54:1629–1636. doi: 10.1093/cid/cis195. PubMed DOI

Lass-Flörl C. Zygomycosis: conventional laboratory diagnosis. Clin Microbiol Infect. 2009;15:60–65. doi: 10.1111/j.1469-0691.2009.02999.x. PubMed DOI

Lass-Flörl C, Mayr A. Diagnosing invasive fungal diseases - limitations of microbiological diagnostic methods. Expert Opin Med Diagn. 2009;3:461–470. doi: 10.1517/17530050902878031. PubMed DOI

Lass-Flörl C, Resch G, Nachbaur D, et al. The value of computed tomography-guided percutaneous lung biopsy for diagnosis of invasive fungal infection in immunocompromised patients. Clin Infect Dis. 2007;45:101–104. doi: 10.1086/521245. PubMed DOI

Lazar S, Lukaszewicz J, Persad K, Reinhardt J (2014) Rhinocerebral Mucor circinelloides infection in immunocompromised patient following yogurt ingestion. Del Med J 86:245–248. https://pubmed.ncbi.nlm.nih.gov/25252436/ PubMed

Lechevalier P, Hermoso DG, Carol A, et al. Molecular diagnosis of Saksenaea vasiformis cutaneous infection after scorpion sting in an immunocompetent adolescent. J Clin Microbiol. 2008;46:3169–3172. doi: 10.1128/JCM.00052-08. PubMed DOI PMC

Ledgard JP, Van Hal S, Greenwood JE. Primary cutaneous zygomycosis in a burns patient: a review. J Burn Care Res. 2008;29:286–290. doi: 10.1097/BCR.0b013e31816673b1. PubMed DOI

Lee JH, Hyun JS, Kang DY, Lee HJ, Park SG. Rare complication of bronchoesophageal fistula due to pulmonary mucormycosis after induction chemotherapy for acute myeloid leukemia: A case report. J Med Case Rep. 2016;10:4–9. doi: 10.1186/s13256-016-0991-7. PubMed DOI PMC

Lelievre L, Garcia-Hermoso D, Abdoul H, et al. Posttraumatic mucormycosis: a nationwide study in France and review of the literature. Med (united States) 2014;93:395–404. doi: 10.1097/MD.0000000000000221. PubMed DOI PMC

Lewis RE, Georgiadou SP, Sampsonas F, Chamilos G, Kontoyiannis DP. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. Mycoses. 2014;57:49–55. doi: 10.1111/myc.12101. PubMed DOI PMC

Li HM, Hwang SK, Zhou C, Du J, Zhang JZ. Gangrenous cutaneous mucormycosis caused by Rhizopus oryzae: a case report and review of primary cutaneous mucormycosis in China over past 20 years. Mycopathologia. 2013;176:123–128. doi: 10.1007/s11046-013-9654-z. PubMed DOI

Lin CY, Liu WL, Chang CC, et al. Invasive fungal tracheobronchitis in mechanically ventilated critically ill patients: underlying conditions, diagnosis, and outcomes. Ann Intensive Care. 2017;7:1–7. doi: 10.1186/s13613-016-0230-9. PubMed DOI PMC

Liu Y, Wu H, Huang F, Fan Z, Xu B. Utility of 18F-FDG PET/CT in diagnosis and management of mucormycosis. Clin Nucl Med. 2013;38:370–371. doi: 10.1097/rlu.0b013e3182867d13. PubMed DOI

Losee JE, Selber J, Vega S, Hall C, Scott G, Serletti JM. Primary cutaneous mucormycosis: guide to surgical management. Ann Plast Surg. 2002;49:385–390. doi: 10.1097/00000637-200210000-00009. PubMed DOI

Machouart M, Larché J, Burton K, et al. Genetic identification of the main opportunistic mucorales by PCR-restriction fragment length polymorphism. J Clin Microbiol. 2006;44:805–810. doi: 10.1128/JCM.44.3.805-810.2006. PubMed DOI PMC

Maertens JA, Raad, II, Marr KA, et al (2016) Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 387:760–769. 10.1016/S0140-6736(15)01159-9 PubMed

Mahajan NN, Pednekar R, Patil SR, et al. Preparedness, administrative challenges for establishing obstetric services, and experience of delivering over 400 women at a tertiary care COVID-19 hospital in India. Int J Gynecol Obstet. 2020;151:188–196. doi: 10.1002/ijgo.13338. PubMed DOI PMC

Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. Int J Surg Case Rep. 2021;82:105957–105961. doi: 10.1016/j.ijscr.2021.105957. PubMed DOI PMC

Manesh A, John AO, Mathew B, et al. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Mycoses. 2016;59:765–772. doi: 10.1111/myc.12529. PubMed DOI

Manesh A, Rupali P, Sullivan MO, et al. Mucormycosis—a clinicoepidemiological review of cases over 10 years. Mycoses. 2019;2019:391–398. doi: 10.1111/myc.12897. PubMed DOI

Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–917. doi: 10.1086/339202. PubMed DOI

Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16:828–837. doi: 10.1016/S1473-3099(16)00071-2. PubMed DOI

Mattingly JK, Ramakrishnan VR. Rhinocerebral mucormycosis of the optic nerve. Otolaryngol - Head Neck Surg (united States) 2016;155:888–889. doi: 10.1177/0194599816658024. PubMed DOI

Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12:e10726–e10731. doi: 10.7759/cureus.10726. PubMed DOI PMC

Mekonnen ZK, Ashraf DC, Jankowski T, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg. 2021;37:E40–E42. doi: 10.1097/IOP.0000000000001889. PubMed DOI PMC

Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, Simko JP, Winn BJ. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. Ophthal Plast Reconstr Surg. 2021;37:e40–e80. doi: 10.1097/IOP.0000000000001889. PubMed DOI PMC

Mellinghoff SC, Bassetti M, Dörfel D, et al (2018) Isavuconazole shortens the QTc interval. Mycoses. 61:256–60. 10.1111/myc.12731 PubMed

Millon L, Herbrecht R, Grenouillet F, et al. Early diagnosis and monitoring of mucormycosis by detection of circulating DNA in serum: retrospective analysis of 44 cases collected through the French Surveillance Network of Invasive Fungal Infections (RESSIF) Clin Microbiol Infect. 2016;22:810.e1–810.e8. doi: 10.1016/j.cmi.2015.12.006. PubMed DOI

Mills SEA, Yeldandi AV, Odell DD. Surgical treatment of multifocal pulmonary mucormycosis. Ann Thorac Surg. 2018;106:e93–e95. doi: 10.1016/j.athoracsur.2017.12.033. PubMed DOI PMC

Monheit JE, Cowan DF, Moore DG (1984) Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med 108:616–628. https://pubmed.ncbi.nlm.nih.gov/6204621/ PubMed

Moreira J, Ridolfi F, Almeida-Paes R, Varon A, Lamas CC. Cutaneous mucormycosis in advanced HIV disease. Brazilian J Infect Dis. 2016;20:637–640. doi: 10.1016/j.bjid.2016.06.004. PubMed DOI PMC

Moreira J, Varon A, Galhardo MC, et al. The burden of mucormycosis in HIV-infected patients: A systematic review. J Infect. 2016;73:181–188. doi: 10.1016/j.jinf.2016.06.013. PubMed DOI

Nagao K, Ota T, Tanikawa A, et al. Genetic identification and detection of human pathogenic Rhizopus species, a major mucormycosis agent, by multiplex PCR based on internal transcribed spacer region of rRNA gene. J Dermatol Sci. 2005;39:23–31. doi: 10.1016/j.jdermsci.2005.01.010. PubMed DOI

Nam Y, Jung J, Park SS, et al. Disseminated mucormycosis with myocardial involvement in a renal transplant recipient. Transpl Infect Dis. 2015;17:890–896. doi: 10.1111/tid.12452. PubMed DOI

Nandwani A, Jha PK, Duggal R, Kher V. Invasive gastric mucormycosis and cytomegalovirus infection in an ABO incompatible renal transplant recipient. Indian J Nephrol. 2015;25:373–376. doi: 10.4103/0971-4065.157428. PubMed DOI PMC

Nasa M, Sharma Z, Lipi L, Sud R (2017) Gastric angioinvasive mucormycosis in immunocompetent adult, a rare occurrence. J Assoc Physicians India 65:103–104. https://pubmed.ncbi.nlm.nih.gov/29327534/ PubMed

Nasir N, Farooqi J, Mahmood SF, Jabeen K. COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: An observational study from Pakistan. Mycoses. 2020;63:766–770. doi: 10.1111/myc.13135. PubMed DOI PMC

Natesan SK, Chandrasekar PH. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: Current evidence, safety, efficacy, and clinical recommendations. Infect Drug Resist. 2016;9:291–300. doi: 10.2147/IDR.S102207. PubMed DOI PMC

Pagano L, Caira M, Nosari A, et al. Fungal infections in recipients of hematopoietic stem cell transplants: Results of the SEIFEM B-2004 study - Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne. Clin Infect Dis. 2007;45:1161–1170. doi: 10.1086/522189. PubMed DOI

Page AV, Evans AJ, Snell L, Liles WC. Primary cutaneous mucormycosis in a lung transplant recipient: Case report and concise review of the literature. Transpl Infect Dis. 2008;10:419–425. doi: 10.1111/j.1399-3062.2008.00324.x. PubMed DOI

Pana ZD, Seidel D, Skiada A, et al. Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries. BMC Infect Dis. 2016;16:1–9. doi: 10.1186/s12879-016-2005-1. PubMed DOI PMC

Park BJ, Pappas PG, Wannemuehler KA, et al. Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001–2006. Emerg Infect Dis. 2011;17:1855–1864. doi: 10.3201/eid1710.110087. PubMed DOI PMC

Pasero D, Sanna S, Liperi C, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020;49:1055–1060. doi: 10.1007/s15010-020-01561-x. PubMed DOI PMC

Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, Simeo R, Buselli A, Rizzo D, Bussu F. A challenging complication following SARS-CoV-2 infection:a case of pulmonary mucormycosis. Infection. 2020;49:1055–1060. doi: 10.1007/s15010-020-01561-x. PubMed DOI PMC

Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26:944–949. doi: 10.1016/j.cmi.2019.11.021. PubMed DOI

Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;63:e1–e60. doi: 10.1093/cid/ciw326. PubMed DOI PMC

Perfect JR, Cornely OA, Heep M, et al. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: challenges and lessons of the VITAL trial. Mycoses. 2018;61:420–429. doi: 10.1111/myc.12769. PubMed DOI PMC

Petrikkos G, Drogari-Apiranthitou M (2011) Zygomycosis in immunocompromised non-haematological patients. Mediterr J Hematol Infect Dis 3:e2011012. 10.4084/MJHID.2011.012 PubMed PMC

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54:23–34. doi: 10.1093/cid/cir866. PubMed DOI

Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54:S23–S34. doi: 10.1093/cid/cir866. PubMed DOI

Petrikkos G, Tsioutis C. Recent advances in the pathogenesis of mucormycoses. Clin Ther. 2018;40:894–902. doi: 10.1016/j.clinthera.2018.03.009. PubMed DOI

Priya P, Ganesan V, Rajendran T, et al. (2020) Mucormycosis in a Tertiary Care Center in South India: A 4-Year Experience. Indian J Crit Care Med 24:168–171. 10.5005/jp-journals-10071-23387 PubMed PMC

Placik DA, Taylor WL, Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. Radiol Case Rep. 2020;15:2378–2381. doi: 10.1016/j.radcr.2020.09.026. PubMed DOI PMC

Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood. 2011;118:5416–5419. doi: 10.1182/blood-2011-07-366526. PubMed DOI

Prabhu S, Alqahtani M, Al Shehabi M. A fatal case of rhinocerebral mucormycosis of the jaw after dental extractions and review of literature. J Infect Public Health. 2018;11:301–303. doi: 10.1016/j.jiph.2017.09.026. PubMed DOI

Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis J Fungi. 2019;5:26–30. doi: 10.3390/jof5010026. PubMed DOI PMC

Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India Microorganisms. 2021;9:1–12. doi: 10.3390/microorganisms9030523. PubMed DOI PMC

Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: epidemiology, diagnosis, and treatment. Med Mycol. 2019;57:395–402. doi: 10.1093/mmy/myy060. PubMed DOI

Pyrgos V, Shoham S, Walsh TJ. Pulmonary zygomycosis. Semin Respir Crit Care Med. 2008;29:111–120. doi: 10.1055/s-2008-1063850. PubMed DOI

Rabin AS, Givertz MM, Couper GS, et al. Risk factors for invasive fungal disease in heart transplant recipients. J Hear Lung Transplant. 2015;34:227–232. doi: 10.1016/j.healun.2014.09.036. PubMed DOI PMC

Radner AB, Witt MD, Edwards JE. Acute Invasive Rhinocerebral Zygomycosis in an Otherwise Healthy Patient. Clin Infect Dis. 1995;20:163–166. doi: 10.1093/clinids/20.1.163. PubMed DOI

Ramani R, Gromadzki S, Pincus DH, Salkin IF, Chaturvedi V. Efficacy of API 20C and ID 32C systems for identification of common and rare clinical yeast isolates. J Clin Microbiol. 1998;36:3396–3398. doi: 10.1128/jcm.36.11.3396-3398.1998. PubMed DOI PMC

Rapidis AD. Orbitomaxillary mucormycosis (zygomycosis) and the surgical approach to treatment: Perspectives from a maxillofacial surgeon. Clin Microbiol Infect. 2009;15:98–102. doi: 10.1111/j.1469-0691.2009.02989.x. PubMed DOI

Reed C, Ibrahim A, Edwards JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother. 2006;50:3968–3969. doi: 10.1128/AAC.01065-06. PubMed DOI PMC

Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev. 2000;13:236–301. doi: 10.1128/CMR.13.2.236-301.2000. PubMed DOI PMC

Riches ML, Trifilio S, Chen M, et al. Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: A CIBMTR infection and immune reconstitution analysis. Bone Marrow Transplant. 2016;51:277–282. doi: 10.1038/bmt.2015.263. PubMed DOI PMC

Rickerts V, Just-Nübling G, Konrad F, et al. Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. Eur J Clin Microbiol Infect Dis. 2006;25:8–13. doi: 10.1007/s10096-005-0078-7. PubMed DOI

Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the mold: a review of mucormycosis and current pharmacological treatment options. Ann Pharmacother. 2016;50:747–757. doi: 10.1177/1060028016655425. PubMed DOI

Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–653. doi: 10.1086/432579. PubMed DOI

Rodríguez JY, Morales-López SE, Rodríguez GJ, et al. Necrotizing fasciitis caused by Apophysomyces variabilis in an immunocompetent patient. Med Mycol Case Rep. 2018;20:4–6. doi: 10.1016/j.mmcr.2017.12.002. PubMed DOI PMC

Rüping MJGT, Heinz WJ, Kindo AJ, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. J Antimicrob Chemother. 2009;65:296–302. doi: 10.1093/jac/dkp430. PubMed DOI

Saegeman V, Maertens J, Meersseman W, Spriet I, Verbeken E, Lagrou K. Increasing incidence of Mucormycosis in university hospital, Belgium. Emerg Infect Dis. 2010;16:1456–1458. doi: 10.3201/eid1609.100276. PubMed DOI PMC

Saldanha M, Reddy R, Vincent MJ. Paranasal mucormycosis in COVID-19 patient. Indian J Otolaryngol Head Neck Surg. 2021;22:1–4. doi: 10.1007/s12070-021-02574-0. PubMed DOI PMC

Salehi M, Ahmadikia K, Badali H, Khodavaisy S. Opportunistic fungal infections in the epidemic area of COVID-19: A clinical and diagnostic perspective from Iran. Mycopathologia. 2020;185:607–611. doi: 10.1007/s11046-020-00472-7. PubMed DOI PMC

Sandven P, Eduard W. Detection and quantitation of antibodies against Rhizopus by enzyme-linked immunosorbent assay. APMIS. 1992;100:981–987. doi: 10.1111/j.1699-0463.1992.tb04029.x. PubMed DOI

Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol. 2021;69:1002–1004. doi: 10.4103/ijo.IJO_3763_20. PubMed DOI PMC

Schrödl W, Heydel T, Schwartze VU, et al. Direct analysis and identification of pathogenic Lichtheimia species by matrix-assisted laser desorption ionization-time of flight analyzer-mediated mass spectrometry. J Clin Microbiol. 2012;50:419–427. doi: 10.1128/JCM.01070-11. PubMed DOI PMC

Schwarz P, Guedouar H, Laouiti F, Grenouillet F, Dannaoui E. Identification of mucorales by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. J Fungi. 2019;5:1–11. doi: 10.3390/jof5030056. PubMed DOI PMC

Schwarz P, Lortholary O, Dromer F, Dannaoui E. Carbon assimilation profiles as a tool for identification of Zygomycetes. J Clin Microbiol. 2007;45:1433–1439. doi: 10.1128/JCM.02219-06. PubMed DOI PMC

Sharma S, Gupta P, Gupta N, Lal A, Behera D, Rajwanshi A. Pulmonary infections in immunocompromised patients: the role of image-guided fine needle aspiration cytology. Cytopathology. 2017;28:46–54. doi: 10.1111/cyt.12359. PubMed DOI

Shigemura T, Nishina S, Nakazawa H, Matsuda K, Yaguchi T, Nakazawa Y. Early detection of Rhizopus DNA in the serum of a patient with rhino-orbital-cerebral mucormycosis following allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2016;103:354–355. doi: 10.1007/s12185-016-1938-x. PubMed DOI

Shirley M, Scott LJ. Isavuconazole: a review in invasive aspergillosis and mucormycosis. Drugs. 2016;6:1647–1657. doi: 10.1007/s40265-016-0652-6. PubMed DOI

Shoham S, Magill SS, Merz WG, et al. Primary treatment of zygomycosis with liposomal amphotericin B: Analysis of 28 cases. Med Mycol. 2010;48:511–517. doi: 10.3109/13693780903311944. PubMed DOI

Skiada A, Lanternier F, Groll AH et al (2013) Diagnosis and treatment of mucormycosis in patients with hematological malignancies: Guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 98:492–504. 10.3324/haematol.2012.065110 PubMed PMC

Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, Petrikkos G. Challenges in the diagnosis and treatment of mucormycosis. Med Mycol. 2018;56:S93–S101. doi: 10.1093/mmy/myx101. PubMed DOI PMC

Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect. 2011;17:1859–1867. doi: 10.1111/j.1469-0691.2010.03456.x. PubMed DOI

Song Y, Qiao J, Giovanni G, et al. Mucormycosis in renal transplant recipients: Review of 174 reported cases. BMC Infect Dis. 2017;17(1):1–6. doi: 10.1186/s12879-017-2381-1. PubMed DOI PMC

Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–569. doi: 10.1128/CMR.18.3.556-569.2005. PubMed DOI PMC

Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev. 2005;18:556–569. doi: 10.1128/CMR.18.3.556-569.2005. PubMed DOI PMC

Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The deferasirox-AmBisome therapy for mucormycosis (Defeat Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67:715–722. doi: 10.1093/jac/dkr375. PubMed DOI PMC

Stanzani M, Battista G, Sassi C, et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis. 2012;54:610–616. doi: 10.1093/cid/cir861. PubMed DOI

Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA - J Am Med Assoc. 2020;324:1330–1341. doi: 10.1001/jama.2020.17023. PubMed DOI PMC

Sun HY, Forrest G, Gupta KL, et al. Rhino-orbital-cerebral zygomycosis in solid organ transplant recipients. Transplantation. 2010;90:85–92. doi: 10.1097/TP.0b013e3181dde8fc. PubMed DOI

Tacke D, Koehler P, Markiefka B, Cornely OA. Our 2014 approach to mucormycosis. Mycoses. 2014;57:519–524. doi: 10.1111/myc.12203. PubMed DOI

Tilak R, Raina P, Gupta SK, Tilak V, Prakash P, Gulati AK. Cutaneous zygomycosis: A possible postoperative complication in immunocompetent individuals. Indian J Dermatol Venereol Leprol. 2009;75:596–599. doi: 10.4103/0378-6323.57722. PubMed DOI

Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102:433–444. doi: 10.3324/haematol.2016.152900. PubMed DOI PMC

Tobón AM, Arango M, Fernández D, Restrepo A. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient : recovery after posaconazole therapy. Clin Infect Dis. 2016;36:1488–1491. doi: 10.1086/375075. PubMed DOI

Tribble DR, Krauss MR, Murray CK, et al. Epidemiology of trauma-related infections among a combat casualty cohort after initial hospitalization: the Trauma Infectious Disease Outcomes Study. Surg Infect (larchmt) 2018;19:494–503. doi: 10.1089/sur.2017.241. PubMed DOI PMC

Tuysuz G, Ozdemir N, Senyuz OF, et al. Successful management of hepatic mucormycosis in an acute lymphoblastic leukaemia patient: a case report and review of the literature. Mycoses. 2014;57:513–518. doi: 10.1111/myc.12184. PubMed DOI

Vehreschild JJ, Birtel A, Vehreschild MJGT, et al. Mucormycosis treated with posaconazole: Review of 96 case reports. Crit Rev Microbiol. 2013;39:310–324. doi: 10.3109/1040841X.2012.711741. PubMed DOI

Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino- orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. Eur J Ophthalmol. 2021;1:1–6. doi: 10.1177/11206721211009450. PubMed DOI PMC

Vitale RG, De Hoog GS, Schwarz P, et al. Antifungal susceptibility and phylogeny of opportunistic members of the order Mucorales. J Clin Microbiol. 2012;50:66–75. doi: 10.1128/JCM.06133-11. PubMed DOI PMC

Vogt N, Heß K, Bialek R, et al. Epileptic seizures and rhinocerebral mucormycosis during blinatumomab treatment in a patient with biphenotypic acute leukemia. Ann Hematol. 2017;96:151–153. doi: 10.1007/s00277-016-2837-1. PubMed DOI

Vujanovic M, Krietsch J, Raso MC et al (2017) Replication fork slowing and reversal upon DNA damage require PCNA polyubiquitination and ZRANB3 DNA translocase activity. Mol cell 67:882–890. 10.1016/j.molcel.2017.08.010 PubMed PMC

Wahba H, Truong MT, Lei X, Kontoyiannis DP, Marom EM. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008;46:1733–1737. doi: 10.1086/587991. PubMed DOI

Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis) Clin Infect Dis. 2012;54(SUPPL. 1):55–60. doi: 10.1093/cid/cir868. PubMed DOI

Wang Y, Zhu M, Bao Y, et al. Cutaneous mucormycosis caused by Rhizopus microsporus in an immunocompetent patient: A case report and review of literature. Med (united States) 2018;97:4. doi: 10.1097/MD.0000000000011141. PubMed DOI PMC

Webb BJ, Ferraro JP, Rea S, Kaufusi S, Goodman BE, Spalding J. Epidemiology and clinical features of invasive fungal infection in a US health care network. Open Forum Infect Dis. 2018;5:2–9. doi: 10.1093/ofid/ofy187. PubMed DOI PMC

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:264.e5–264.e8. doi: 10.1016/j.ajem.2020.09.032. PubMed DOI PMC

Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. Am J Emerg Med. 2021;42:e245–e264. doi: 10.1016/j.ajem.2020.09.032e265-264.e268. PubMed DOI PMC

White PL, Dhillon R, Cordey A, et al. A national stretegy to diagnose COVID-19 associated invasive fungal disease in the ICU. SSRN. 2020;73:1–34. doi: 10.2139/ssrn.3644400. PubMed DOI

Wysong DR, Waldorf AR. Electrophoretic and immunoblot analyses of Rhizopus arrhizus antigens. J Clin Microbiol. 1987;25:358–363. doi: 10.1128/jcm.25.2.358-363.1987. PubMed DOI PMC

Yang M, Lee JH, Kim YK, Ki CS, Huh HJ, Lee NY. Identification of mucorales from clinical specimens: A 4-year experience in a single institution. Ann Lab Med. 2016;36:60–63. doi: 10.3343/alm.2016.36.1.60. PubMed DOI PMC

Zilberberg MD, Shorr AF, Huang H, Chaudhari P, Paly VF, Menzin J. Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data. BMC Infect Dis. 2014;14:1–10. doi: 10.1186/1471-2334-14-310. PubMed DOI PMC